Michael Ryskin
BofA Securities, Research Division

[Audio Gap] Medical Life Science Tools and Diagnostics team, and I'm very excited to be hosting Danaher. I'm joined by Rainer Blair, Chief Executive Officer.

Rainer Blair
President, CEO & Director

Good day, everyone. Thanks for having us, Mike.

Michael Ryskin
BofA Securities, Research Division

Always great to have you here. Really pleasure. We'll just do a fireside chat, but if there's any really burning questions, please throw up your hand. Maybe just to kick things off. Just a couple of weeks ago, you reported 1Q. You saw 50 bps operational core growth, but there was a respiratory dynamic there as well. Strong earnings growth despite that, and you provided an update for the full year guide. Maybe just talk through real quickly how the quarter played out relative to expectations? What was maybe a little bit stronger or was maybe a little bit more challenging? What surprised you?

Rainer Blair
President, CEO & Director

Sure. It was a solid quarter. We saw our end markets as well as the momentum across the business to be actually a little bit better than we thought. If you take out respiratory, just as you mentioned, we had 300 basis points of growth, and we thought that was pretty solid. The ILI, of course, anticipated that respiratory would be a little bit softer. And as we think about the end markets there, we look at bioprocessing. Bioprocessing came in at high single digits driven by consumables. But I think a nice point of confirmation that the activity levels are getting better was the year-over-year orders growth in equipment, which was over 30%.